Modeling the logistics of response to anthrax bioterrorism.
BACKGROUND
A bioterrorism attack with an agent such as anthrax will require rapid deployment of medical and pharmaceutical supplies to exposed individuals. How should such a logistical system be organized? How much capacity should be built into each element of the bioterrorism response supply chain?


METHODS
The authors developed a compartmental model to evaluate the costs and benefits of various strategies for preattack stockpiling and postattack distribution and dispensing of medical and pharmaceutical supplies, as well as the benefits of rapid attack detection.


RESULTS
The authors show how the model can be used to address a broad range of logistical questions as well as related, nonlogistical questions (e.g., the cost-effectiveness of strategies to improve patient adherence to antibiotic regimens). They generate several key insights about appropriate strategies for local communities. First, stockpiling large local inventories of medical and pharmaceutical supplies is unlikely to be the most effective means of reducing mortality from an attack, given the availability of national and regional supplies. Instead, communities should create sufficient capacity for dispensing prophylactic antibiotics in the event of a large-scale bioterror attack. Second, improved surveillance systems can significantly reduce deaths from such an attack but only if the local community has sufficient antibiotic-dispensing capacity. Third, mortality from such an attack is significantly affected by the number of unexposed individuals seeking prophylaxis and treatment. Fourth, full adherence to treatment regimens is critical for reducing expected mortality.


CONCLUSIONS
Effective preparation for response to potential bioterror attacks can avert deaths in the event of an attack. Models such as this one can help communities more effectively prepare for response to potential bioterror attacks.
Zaric
Gregory S
GS
Ivey School of Business, University of Western Ontario, Canada. gzaric@ivey.uwo.ca
Bravata
Dena M
DM
Cleophas Holty
Jon-Erik
JE
McDonald
Kathryn M
KM
Owens
Douglas K
DK
Brandeau
Margaret L
ML
D000881:Anthrax / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D000900:Anti-Bacterial Agents / Q000600:supply & distribution / Q000627:therapeutic use; D023482:Bioterrorism; D004189:Disaster Planning / Q000458:organization & administration*; D006801:Humans; D008962:Models, Theoretical; D014481:United States / Q000453:epidemiology
D000900:Anti-Bacterial Agents